Belgian nuclear medicine products firm Ion Beam Applications (IBA) has signed a contract manufacturing and distribution agreement with SAIC-Frederick.
Operating under the Frederick, MD-based firm's prime contract with the National Cancer Institute (NCI), IBA Molecular will produce and distribute F-18 galacto-RGD for NCI-sponsored clinical trials.
The PET imaging agent can be used for the noninvasive determination of ανß3 integrin expression, according to IBA of Louvain-la-Neuve, Belgium.
In other IBA news, the firm said it will be introducing several new PET and therapeutic radionuclides and tracers for the European and world markets, including iodine-124, zirconium-89, and astatine-211.
By AuntMinnie.com staff writers
October 2, 2006
Related Reading
IBA shows financial gains in Q2, September 18, 2006
IBA to deliver cyclotron facility to Turkey, August 29, 2006
IBA launches synthesizer, new corporate look, June 7, 2006
Eastern Isotopes changes identity, April 21, 2006
Schering, IBA ink radiopharma deal, February 23, 2006
Copyright © 2006 AuntMinnie.com
